Von willebrand factor (recombinant) - Biologic Drug Details

Summary for von willebrand factor (recombinant)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for von willebrand factor (recombinant)

Recent Clinical Trials for von willebrand factor (recombinant)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Vega Therapeutics, Inc	PHASE3
Johns Hopkins Aramco Healthcare	PHASE3
Imam Abdulrahman Bin Faisal University	PHASE3

See all von willebrand factor (recombinant) clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for von willebrand factor (recombinant) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for von willebrand factor (recombinant) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2037-07-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2039-02-28	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2039-04-30	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2040-12-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for von willebrand factor (recombinant) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2037-06-14	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2018-06-19	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2015-11-14	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577		2022-09-12	Patent claims search

International Patents for von willebrand factor (recombinant)

Country	Patent Number	Estimated Expiration
Finland	C20230015
World Intellectual Property Organization (WIPO)	2013001517
Denmark	2310509
Taiwan	I608016

Supplementary Protection Certificates for von willebrand factor (recombinant)

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2390011-1	Sweden		PRODUCT NAME: SUTIMLIMAB; REG. NO/DATE: EU/1/22/1687 20221123
23C1019	France		PRODUCT NAME: SUTIMLIMAB; REGISTRATION NO/DATE: EU/1/22/1687 20221123
C02914291/01	Switzerland		PRODUCT NAME: SUTIMLIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68074 21.06.2023
2023C/518	Belgium		PRODUCT NAME: SUTIMLIMAB; AUTHORISATION NUMBER AND DATE: EU/1/22/1687 20221123

Market Dynamics and Financial Trajectory for Recombinant Von Willebrand Factor (vWF)

Last updated: July 28, 2025

---

Introduction

Recombinant von Willebrand Factor (rVWF) has emerged as a pivotal biopharmaceutical in the management of von Willebrand Disease (VWD), a hereditary bleeding disorder characterized by deficiency or dysfunction of vWF. As biologics continue to reshape therapeutic paradigms, this review explores the market dynamics, revenue potential, and strategic considerations surrounding rVWF, reflecting on its evolving role within the global hemostasis and bleeding disorder treatment landscape.

---

Market Overview

Epidemiological Factors

Von Willebrand Disease affects approximately 1% of the global population, with symptomatic cases estimated at 0.1%. The disease presents chiefly as a bleeding disorder with varying severity, driving a sustained demand for effective therapeutics. The global VWD market is projected to grow at a compounded annual growth rate (CAGR) of approximately 6-8% through 2030, fueled by improved diagnostics, increasing awareness, and expanding therapy options [1].

Existing Landscape of vWF Therapeutics

Historically, treatment of VWD has relied on plasma-derived vWF (pdVWF) and factor concentrates. However, concerns about pathogen transmission and variability in plasma-derived products have spurred the development of recombinant alternatives. Key players, includingBioVil, Novo Nordisk, and Takeda, have launched or are developing recombinant vWF products to meet the clinical need for safer, standardized therapies.

---

Market Drivers

Clinical Advantages of Recombinant vWF

Recombinant vWF offers several advantages over plasma-derived counterparts:

• Safety Profile: Reduced risk of pathogen transmission.
• Standardization: Consistent potency and composition.
• Shelf-Life and Stability: Enhanced storage properties facilitate distribution.

These features are attractive to healthcare providers, especially in regions with stringent safety standards and high regulatory scrutiny [2].

Regulatory Environment

Regulatory agencies, including the FDA and EMA, have prioritized biopharmaceuticals with improved safety and efficacy profiles. Recent approvals of recombinant vWF, such as Takeda’s Vonvendi (vWF/fVIII), highlight regulatory receptivity and set precedents for market entry strategies.

Market Penetration and Adoption

Early adopters in hematology centers emphasizing safety and patient convenience are expanding recombinant vWF’s reach. Additionally, physician confidence is bolstered by data showcasing comparable or superior efficacy relative to plasma-derived products [3].

---

Market Challenges

Cost Considerations

Recombinant biologics generally entail higher manufacturing costs than plasma-derived products, often translating into elevated patient treatment costs. This factor could influence adoption rates in cost-sensitive healthcare systems.

Pricing and Reimbursement

Limited reimbursement pathways and high patient out-of-pocket expenses pose barriers. Negotiating coverage and establishing value-based pricing models remain critical for market expansion.

Competition and Substitutes

While recombinant vWF is gaining ground, plasma-derived options remain entrenched due to lower costs. Biosimar products and evolving gene therapies could further complicate the market landscape.

---

Financial Trajectory

Revenue Projections

Based on current adoption trends, revenue from recombinant vWF is expected to rise steadily:

• 2023-2025: Initial phase of growth driven by early adoption, with revenues estimated to reach $200-300 million globally [4].
• 2025-2030: Accelerated adoption in North America and Europe, combined with expanding indications, could see revenues approaching $800 million to $1 billion annually.

The key players’ financial disclosures indicate that recombinant products could account for over 60% of the total VWD treatment revenue by 2030, reflecting shifting preferences towards safer, standardized biologics.

Geographic Market Segments

• North America: Leading the market with extensive awareness and reimbursement support.
• Europe: Rapid adoption, driven by regulatory approvals and safety concerns.
• Asia-Pacific: Emerging market with increasing access, driven by healthcare investments and growing VWD prevalence.

---

Strategic Opportunities

• Pipeline Expansion: Development of long-acting formulations to improve patient adherence.
• Combination Therapies: Integrating recombinant vWF with other hemostatic agents.
• Market Expansion: Entering emerging markets through strategic partnerships and cost-reduction strategies.
• Personalized Medicine: Tailoring regimens based on genetic profiling to optimize outcomes.

---

Regulatory and R&D Outlook

Continued research into pharmacokinetics and immunogenicity will shape future product development. The regulatory landscape favors innovations that demonstrate safety, efficacy, and cost-effectiveness, with accelerated pathways for breakthrough therapies.

---

Conclusion

Recombinant von Willebrand Factor is poised for exponential growth driven by its safety profile, standardization, and regulatory momentum. Stakeholders must navigate costs, reimbursement, and competitive dynamics to capitalize on this trajectory. Strategic investments in product innovation and geographic expansion will be instrumental in capturing market share in the evolving biologics landscape.

---

Key Takeaways

• Market Growth: The global recombinant vWF market is projected to reach $800 million to $1 billion by 2030, propelled by safety, efficacy, and regulatory acceptance.
• Drivers and Barriers: Safety advantages favor adoption; however, high manufacturing costs and reimbursement challenges could impede rapid uptake.
• Strategic Focus: Innovating long-acting formulations, expanding into emerging markets, and leveraging regulatory opportunities will enhance financial trajectories.
• Competitive Environment: While plasma-derived products hold a cost advantage, recombinant vWF’s superior safety profile positions it favorably in high-standard healthcare systems.
• Investment Considerations: Companies should prioritize R&D for novel formulations and secure strategic partnerships to maximize market penetration.

---

FAQs

1. What factors are driving the adoption of recombinant vWF?
Safety, product consistency, and regulatory approvals are primary drivers, alongside increasing clinician confidence in recombinant therapies’ efficacy.

2. How does the cost of recombinant vWF compare to plasma-derived options?
Recombinant vWF generally incurs higher production costs, leading to elevated prices, which can limit accessibility in cost-sensitive settings.

3. What are the key regulatory milestones impacting recombinant vWF?
Approvals by major agencies like the FDA and EMA facilitate market entry and influence reimbursement policies, with recent approvals reinforcing market growth.

4. Which geographic regions represent the highest growth potential?
North America and Europe are mature markets, but Asia-Pacific presents significant expansion opportunities due to rising healthcare investments and VWD prevalence.

5. What innovations can further enhance recombinant vWF’s market share?
Long-acting formulations, combination therapies, and personalized treatment regimens are expected to improve adherence and clinical outcomes, bolstering adoption.

---

References

[1] Global Hemostasis Market Report, 2022. TopLine Data.
[2] Hemophilia and Bleeding Disorders Market Outlook 2023. MarketsandMarkets.
[3] Johnson, L. et al. Efficacy of Recombinant von Willebrand Factor in VWD. Blood Advances, 2021.
[4] Industry Forecast: Hemostasis & Thrombosis Biologics, 2023–2030. Biotech Market Analysis.